Nimbus, Bristol-Myers Drop Psoriasis Drug Dispute

By Matthew Perlman (January 4, 2022, 6:25 PM EST) -- Nimbus Therapeutics LLC agreed Tuesday to drop its case in New York federal court that sought to avoid selling Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. a psoriasis drug the startup is developing.

Nimbus, Bristol-Myers and Celgene filed a stipulation dismissing antitrust and contract claims from Nimbus and counterclaims from the other companies. The stipulation also said a preliminary injunction issued by the court in October preventing transfer of assets associated with the treatment "will no longer remain in effect."

In a statement on Tuesday, a representative for Nimbus said the companies have reached an agreement "resolving all claims and business...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!